

SEATTLE GENETICS INC /WA  
Form 8-K  
November 02, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 30, 2012**

**Seattle Genetics, Inc.**

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**0-32405**  
(Commission

File Number)  
21823 30<sup>th</sup> Drive SE

Bothell, Washington 98021

**91-1874389**  
(I.R.S. Employer

Identification No.)

Edgar Filing: SEATTLE GENETICS INC /WA - Form 8-K

(Address of principal executive offices, including zip code)

(425) 527-4000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) On October 30, 2012, Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics, Inc. ( Seattle Genetics or the Company ), informed the Company of his resignation in connection with his retirement for a family health matter. Dr. Reynolds will continue to serve as the Company s Chief Medical Officer until December 31, 2012. Dr. Reynolds has been a key contributor at Seattle Genetics, notably through his leadership of the Company s clinical and regulatory teams during the development and approval of ADCETRIS. The Company has started a search for a replacement to Dr. Reynolds and anticipates a seamless transition of responsibilities over the next several months.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SEATTLE GENETICS, INC.**

Date: November 2, 2012

By: /s/ Eric L. Dobmeier  
Eric L. Dobmeier

Chief Operating Officer